Discover investment opportunities in Top 30 Stocks Under $4 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 30 Stocks Under $4 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 30 Stocks Under $4 using our Smart AI Filter.
9 stocks found for "Top 30 Stocks Under $4"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.69 | ±26.2% | 7.1 | 16.46% | |||
1.00 | ±75.3% | 70.6 | 0.00% | |||
1.79 | ±83.9% | -4.3 | 0.68% | |||
1.28 | ±83.4% | 51.3 | 0.00% | |||
1.45 | ±61.6% | -31.7 | 16.80% | |||
0.05 | ±100.0% | — | 0.00% | |||
1.00 | ±57.1% | 11.5 | 0.00% | |||
2.47 | ±98.2% | -13.0 | 0.00% | |||
0.35 | ±100.0% | -0.5 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Novo Nordisk A/S is slashing the cost of Ozempic for cash-paying patients to $499 a month through NovoCare and partnering with GoodRx Holdings Inc. to offer it at the same price at US pharmacies. Bloomberg's Madison Muller reports.
Read moreQ: What are the potential benefits of investing in low-priced stocks like SYTA and AMC?
A: Low-priced stocks, such as SYTA and AMC, can be appealing due to their low entry cost, offering the potential for substantial appreciation. They often attract retail investors looking for growth opportunities. However, these stocks can also display higher volatility and risk, requiring careful research and portfolio diversification.
Q: How has JMIA performed historically in e-commerce markets?
A: JMIA, known as Jumia Technologies, has had varied performance in African e-commerce markets. It faces the challenge of operating in diverse and fragmented markets, leading to fluctuating revenue and stock performance. Investors should review financial reports and market trends for a clearer perspective.
Q: Is GDRX suitable for tech-inclined investors seeking growth?
A: GDRX, GoodRx Holdings, specializes in digital health platforms and may interest investors focused on technology and healthcare. It has experienced growth by offering cost-saving solutions for prescription medications. However, industry competition and pricing pressures pose potential risks.
Q: How is PSEC positioned within the financial sector for income seekers?
A: PSEC, or Prospect Capital Corporation, is a business development company often favored by income-focused investors due to its high dividend yields. While it offers attractive payouts, investors should assess the sustainability of dividends based on cash flow and earnings reports.
Q: What economic factors affect the media company GCI's performance?
A: GCI, Gannett Co., operates in the media sector, influenced by digital transformation, advertising revenues, and audience engagement. Economic downturns can affect advertising spend, impacting GCI's financial health. Monitoring sector trends and company initiatives toward digital adaptation is advisable.
Q: Are stocks like BLSK and EXK viable for investors interested in commodities?
A: BLSK (BoneSpring Hosting) and EXK (Endeavour Silver Corp) vary in their commodity focus. EXK offers exposure to the precious metals sector, potentially benefiting from commodity price increases. BLSK requires investigation as specific commodity ties are not clear from the ticker alone.